06.11.18
Neptune unveiled the publication of a new randomized, double-blind, pilot human clinical trial, which studied the impact of MaxSimil (monoglyceride MAG DHA) on red blood cells fatty acid profile. The study also examined levels of inflammatory biomarkers in a population inflicted with cystic fibrosis (CF).
Cystic fibrosis patients generally suffer from exocrine pancreatic insufficiency (EPI), a condition that prevents the proper production of enzymes the body requires to break down and absorb nutrients and dietary fatty acids. The lack of digestive enzymes often leads to fat malabsorption and malnutrition.
Conditions leading to fat malabsorption have been associated with a high incidence of essential fatty acid deficiency (EFAD). In CF patients, a high EFAD incidence (85%) has been frequently reported and often results in a decrease in linoleic acid and docosahexaenoic acid (DHA) in addition to an increase in arachidonic acid (AA). This creates an imbalance in the AA/DHA ratio in favor of AA and may contribute to an increase in inflammation.
For cystic fibrosis patients and with one month of supplementation of MaxSimil DHA taken at bedtime without any added enzymes, the study revealed that MaxSimil DHA was efficient in:
Additional studies with larger patient populations and longer study duration are now required to confirm these encouraging results.
Cystic fibrosis patients generally suffer from exocrine pancreatic insufficiency (EPI), a condition that prevents the proper production of enzymes the body requires to break down and absorb nutrients and dietary fatty acids. The lack of digestive enzymes often leads to fat malabsorption and malnutrition.
Conditions leading to fat malabsorption have been associated with a high incidence of essential fatty acid deficiency (EFAD). In CF patients, a high EFAD incidence (85%) has been frequently reported and often results in a decrease in linoleic acid and docosahexaenoic acid (DHA) in addition to an increase in arachidonic acid (AA). This creates an imbalance in the AA/DHA ratio in favor of AA and may contribute to an increase in inflammation.
For cystic fibrosis patients and with one month of supplementation of MaxSimil DHA taken at bedtime without any added enzymes, the study revealed that MaxSimil DHA was efficient in:
- Increasing omega-3 fatty acid red blood cells levels in individuals that do not have the capacity to produce their own enzymes and have related digestive issues;
- Increasing DHA red blood cells levels;
- Decreasing and correcting AA/DHA ratio;
- Reducing key inflammatory biomarkers (pHLE and IL-6) in blood samples of supplemented patients which highlights the anti-inflammatory benefits of the MaxSimil fish oil.
Additional studies with larger patient populations and longer study duration are now required to confirm these encouraging results.
